RTI Surgical (NASDAQ: RTIX) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its rivals? We will compare RTI Surgical to similar companies based on the strength of its earnings, risk, profitability, analyst recommendations, dividends, valuation and institutional ownership.
This table compares RTI Surgical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RTI Surgical Competitors||-101.23%||-92.70%||-30.32%|
This table compares RTI Surgical and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|RTI Surgical||$272.86 million||-$14.39 million||-64.29|
|RTI Surgical Competitors||$1.67 billion||$207.58 million||85.24|
RTI Surgical’s rivals have higher revenue and earnings than RTI Surgical. RTI Surgical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
69.9% of RTI Surgical shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 4.9% of RTI Surgical shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for RTI Surgical and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RTI Surgical Competitors||111||730||1026||10||2.50|
As a group, “Medical Devices & Implants” companies have a potential upside of 37.06%. Given RTI Surgical’s rivals higher possible upside, analysts plainly believe RTI Surgical has less favorable growth aspects than its rivals.
Risk & Volatility
RTI Surgical has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, RTI Surgical’s rivals have a beta of 0.47, indicating that their average stock price is 53% less volatile than the S&P 500.
RTI Surgical beats its rivals on 6 of the 10 factors compared.
About RTI Surgical
RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.
Receive News & Ratings for RTI Surgical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc and related companies with MarketBeat.com's FREE daily email newsletter.